BACKGROUND: Patients with obstructive sleep apnea (OSA) are at increased risk of postoperative cardiorespiratory complications and death. Attempts to stratify this risk have been inadequate, and predictors from large well-characterized cohort studies are needed.
OBJECTIVE: What is the relationship between OSA severity, defined by various polysomnography-derived metrics, and risk of postoperative cardiorespiratory complications or death, and which metrics best identify such risk?
METHODS: Cohort study of 6770 consecutive patients who underwent diagnostic polysomnography for possible OSA and a procedure involving general anesthesia within a period spanning 2 years before and at least 5 years after polysomnography. Participants were identified by linking polysomnography and health databases. Relationships between OSA severity measures and the composite primary outcome of cardiorespiratory complications or death within 30 days of hospital discharge were investigated using univariable and multivariable analyses.
RESULTS: The primary outcome was observed in 5.3% (n=361) of the cohort. While univariable analysis showed strong dose-response relationships between this outcome and multiple OSA severity measures, multivariable analysis showed its independent predictors were: age >65 years (OR 2.67 [95%CI 2.03-3.52], p<0.0001); age 55.1-65 years (OR 1.47 [1.09-1.98], p=0.0111); time between polysomnography and procedure ≥5 years (OR 1.32 [1.02-1.70], p=0.0331), body mass index ≥35kg/m2 (OR 1.43 [1.13-1.82], p=0.0032); presence of known cardiorespiratory risk factor (OR 1.63 [1.29-2.06], p<0.0001); >4.7% of sleep time at SpO2 less than 90% (T90) (OR 1.91 [1.51-2.42], p<0.0001); and cardiothoracic procedures (OR 7.95 [5.71-11.08], p<0.001). For non-cardiothoracic procedures, age, BMI, presence of known cardiorespiratory risk factor and T90 remained the significant predictors, and a risk score based on their odds ratios was predictive of outcome (area under receiver operating characteristic curve 0.7 [95%CI 0.64-0.75]).
CONCLUSIONS: These findings provide a basis for better identifying high-risk OSA patients and determining appropriate postoperative care.

In the last years, the hypothesis of a close relationship between sleep disorders (SDs) and Parkinson\'s disease (PD) has significantly strengthened. Whether this association is causal has been also highlighted by recent evidence demonstrating a neurobiological link between SDs and PD. Thus, the question is not whether these two chronic conditions are mutually connected, but rather how and when this relationship is expressed. Supporting this, not all SDs manifest with the same temporal sequence in PD patients. Indeed, SDs can precede or occur concomitantly with the onset of the clinical manifestation of PD. This review discusses the existing literature, putting under a magnifying glass the timing of occurrence of SDs in PD-neurodegeneration. Based on this, here, we propose two possible directions for studying the SDs-PD relationship: the first direction, from SDs to PD, considers SDs as potential biomarker/precursor of future PD-neurodegeneration; the second direction, from PD to SDs, considers SDs as concomitant symptoms in manifest PD, mainly related to primary PD-neuropathology and/or parkinsonian drugs. Furthermore, for each direction, we questioned SDs-PD relationship in terms of risk factors, neuronal circuits/mechanisms, and impact on the clinical phenotype and disease progression. Future research is needed to investigate whether targeting sleep may be the winning strategy to treat PD, in the context of a personalized precision medicine.

OBJECTIVE: Since 2019, the FDA has cleared nine novel obstructive sleep apnea (OSA)-detecting wearables for home sleep apnea testing, with many now commercially available for sleep clinicians to integrate into their clinical practices. To help clinicians comprehend these devices and their functionalities, we meticulously reviewed their operating mechanisms, sensors, algorithms, data output, and related performance evaluation literature.
METHODS: We collected information from PubMed, FDA clearance documents, ClinicalTrial.gov, and web sources, with direct industry input whenever feasible.
RESULTS: In this \"device-centered\" review, we broadly categorized these wearables into two main groups: those that primarily harness Photoplethysmography (PPG) data and those that do not. The former include the peripheral arterial tonometry (PAT)-based devices. The latter was further broken down into two key subgroups: acoustic-based and respiratory effort-based devices. We provided a performance evaluation literature review and objectively compared device-derived metrics and specifications pertinent to sleep clinicians. Detailed demographics of study populations, exclusion criteria, and pivotal statistical analyses of the key validation studies are summarized.
CONCLUSIONS: In the foreseeable future, these novel OSA-detecting wearables may emerge as primary diagnostic tools for patients at risk for moderate-to-severe OSA without significant comorbidities. While more devices are anticipated to join this category, there remains a critical need for cross-device comparison studies as well as independent performance evaluation and outcome research in diverse populations. Now is the moment for sleep clinicians to immerse themselves in understanding these emerging tools to ensure our patient-centered care is improved through the appropriate implementation and utilization of these novel sleep technologies.

UNASSIGNED: Stuttering priapism is recurrent, self-limited episodes of sustained penile erection and is common in patients with sickle cell disease (SCD). Prevention of stuttering priapism is important to avoid progression to episodes of ischemic priapism which can cause erectile dysfunction. Priapism has been shown to be associated with increased nocturnal hypoxemia in patients with SCD.
UNASSIGNED: A 43-year-old male with nocturnal episodes of stuttering priapism that was refractory to treatment with multiple medications was found to have obstructive sleep apnea (OSA). Following treatment of this condition with a continuous positive airway pressure (CPAP), the patient had immediate symptom relief and has had three months without an episode of priapism.
UNASSIGNED: OSA should be considered as an underlying cause of nocturnal stuttering priapism in patients with SCD, particularly in patients who present with stuttering priapism later in life or patients who present strictly with nocturnal episodes. Appropriate management of OSA can significantly decrease the incidence of stuttering priapism in patients with SCD.

Background and Objectives: Obstructive sleep apnea (OSA) is a prevalent sleep-disordered breathing pathology with significant clinical consequences, including increased cardiovascular risk and cognitive decline. Continuous positive airway pressure (CPAP) is the gold-standard treatment, but alternative strategies are sometimes needed for patients intolerant to CPAP. Drug-induced sleep endoscopy (DISE) is a key diagnostic tool for assessing upper airway obstruction in OSA patients and subsequently tailoring a surgical approach, with sedation protocols playing a crucial role in its efficacy and results accuracy. This study aimed to investigate the effect of adding remifentanil to a propofol target-controlled infusion (TCI) regimen on the sedation parameters and procedural outcomes of DISE. Materials and Methods: The study was conducted at the Central University and Emergency Military Hospital \"Dr. Carol Davila\" and Ria Clinic in Bucharest between July 2021 and October 2023. Thirty-one patients were enrolled and randomised into two groups: a propofol group (P group, n= 11) and a remifentanil-propofol group (R-P group, n = 20). DISE was performed using standardised protocols, sedative drugs were administered in TCI mode, and data on sedation levels, respiratory and cardiovascular parameters, and procedural incidents were collected. Results: The addition of remifentanil at 1 ng/mL effect-site concentration significantly reduced the effect-site concentration of propofol required for adequate sedation (3.4 ± 0.7 µg/mL in the P group vs. 2.8 ± 0.6 µg/mL in the R-P group, p = 0.035). The time to achieve adequate sedation was also shorter in the R-P group (7.1 ± 2.5 min vs. 9.5 ± 2.7 min, p = 0.017). The incidence of cough, hypoxemia, and cardiovascular events did not significantly differ between the two groups. Conclusions: Adding remifentanil to a propofol TCI regimen for DISE effectively reduces the required propofol effect-site concentration and shortens sedation time without increasing the risk of adverse events. This combination may enhance the safety and efficiency of DISE, offering a promising alternative for patients undergoing this procedure.

BACKGROUND: Although related, the precise mechanisms linking obstructive sleep apnea (OSA) and cardiovascular disease (CVD) are unclear. Platelets are mediators of CVD risk and thrombosis and prior studies suggested associations of OSA and platelet activity. The aim of this study is to assess the link between OSA, platelet activity, and CVD-related risk factors.
RESULTS: We studied the association of OSA-measures and platelet aggregation in participants dually enrolled in the SHHS (Sleep Heart and Health Study) and FHS (Framingham Heart Study). We applied linear regression models with adjustment for demographic and clinical covariates and explored interactions with OSA and CVD-related factors, including age, sex, body mass index, hypertension, OSA diagnosis (apnea-hypopnea index 4%≥5), and aspirin use. Our final sample was of 482 participants (60 years [14.00], 50.4% female). No associations were observed between apnea-hypopnea index 4% and platelet aggregation in the main sample. Stratified analysis revealed an association in aspirin users (n=65) for our primary exposure (apnea-hypopnea index 4%, β=0.523; P<0.001; n=65), and secondary exposures: hypoxic burden (β=0.358; P<0.001), minimum saturation (β=-0.519; P=0.026), and oxygen desaturation index 3% (β=74.672; P=0.002). No associations were detected in nonaspirin users (n=417).
CONCLUSIONS: No associations were detected between OSA and platelet aggregation in a community sample. Our finding that OSA associates with increased platelet aggregation in the aspirin group, most of whom use it for primary prevention of CVD, suggests that platelet aggregation may mediate the adverse impact of OSA on vascular health in individuals with existing CVD risk, supporting further investigation.

OBJECTIVE: Upper airway stimulation effectively treats patients with obstructive sleep apnea, especially among those with low long-term compliance with continuous positive airway pressure. Traditional methods to implant the hypoglossal nerve stimulator involve retraction of the digastric tendon to identify the nerve and improve exposure for stimulator implantation. Transient submental pain and discomfort are known side effects of the procedure. Placement without retraction provides an alternative approach to minimize postoperative pain. This study compares post-operative pain outcomes of patients in whom the digastric tendon was and was not retracted.
METHODS: Retrospective chart review of patients who received the hypoglossal nerve stimulation implant at a single institution between 2017 and 2021. A combination of descriptive and qualitative data, including age, gender, comorbidities, and postoperative symptoms are analyzed to characterize patient outcomes resulting from this intraoperative technique. The categorical and continuous variables were analyzed using chi-squared tests and independent t-tests, respectively.
RESULTS: Patients report overall satisfaction after implantation and titration. A total of 108 patients underwent HGNS implantation between September 2017 and January 2021 using the aforementioned techniques. 1.69 % of patients experienced postoperative submental pain as compared to 18.37 % prior to the change in technique (p < 0.01).
CONCLUSIONS: Avoidance of digastric tendon retraction in the implantation of the stimulating lead is a safe and effective technique that reduces postoperative pain and discomfort. Our institution has demonstrated an alternative technique for hypoglossal stimulator implantation which improves perioperative outcomes.
BACKGROUND: Upper airway stimulation is an effective treatment for obstructive sleep apnea. During surgery, the digastric tendon is often moved to identify the nerve and improve access. This study shows that avoiding digastric tendon movement safely reduces postoperative pain and discomfort.
METHODS: III.

OBJECTIVE: To compare the accuracy and generalizability of an automated deep neural network and the Philip Sleepware G3™ Somnolyzer system (Somnolyzer) for sleep stage scoring using American Academy of Sleep Medicine (AASM) guidelines.
METHODS: Sleep recordings from 104 participants were analyzed by a convolutional neural network (CNN), the Somnolyzer and skillful technicians. Evaluation metrics were derived for different combinations of sleep stages. A further comparison between the Somnolyzer and the CNN model using a single-channel signal as input was also performed. Sleep recordings from 263 participants with a lower prevalence of OSA served as a cross-validation dataset to validate the generalizability of the CNN model.
RESULTS: The overall agreement between automated and manual scoring for sleep staging in 104 participants outperformed that of the Somnolyzer according to various metrics (accuracy: 81.81 % vs. 77.07 %; F1: 76.36 % vs. 73.80 %; Cohen\'s kappa: 0.7403 vs. 0.6848). The results showed that the left electrooculography (EOG) single-channel model had minor advantages over the Somnolyzer. In terms of consistency with manual sleep staging, the CNN model demonstrated superior performance in identifying more pronounced sleep transitions, particularly in the N2 stage and sleep latency metrics. Conversely, the Somnolyzer showed enhanced proficiency in the analysis of REM stages, notably in measuring REM latency. The accuracy in the cross-validation set of 263 participants was also above 80 %.
CONCLUSIONS: The CNN-based automated deep neural network outperformed the Somnolyzer and is sufficiently accurate for sleep study analyses using the AASM classification criteria.

The fine identification of sleep apnea events is instrumental in Obstructive Sleep Apnea (OSA) diagnosis. The development of sleep apnea event detection algorithms based on polysomnography is becoming a research hotspot in medical signal processing. In this paper, we propose an Inverse-Projection based Visualization System (IPVS) for sleep apnea event detection algorithms. The IPVS consists of a feature dimensionality reduction module and a feature reconstruction module. First, features of blood oxygen saturation and nasal airflow are extracted and used as input data for event analysis. Then, visual analysis is conducted on the feature distribution for apnea events. Next, dimensionality reduction and reconstruction methods are combined to achieve the dynamic visualization of sleep apnea event feature sets and the visual analysis of classifier decision boundaries. Moreover, the decision-making consistency is explored for various sleep apnea event detection classifiers, which provides researchers and users with an intuitive understanding of the detection algorithm. We applied the IPVS to an OSA detection algorithm with an accuracy of 84% and a diagnostic accuracy of 92% on a publicly available dataset. The experimental results show that the consistency between our visualization results and prior medical knowledge provides strong evidence for the practicality of the proposed system. For clinical practice, the IPVS can guide users to focus on samples with higher uncertainty presented by the OSA detection algorithm, reducing the workload and improving the efficiency of clinical diagnosis, which in turn increases the value of trust.

BACKGROUND: The relationship between obstructive sleep apnea (OSA) and the occurrence of arrhythmias and heart rate variability (HRV) in hypertensive patients is not elucidated. Our study investigates the association between OSA, arrhythmias, and HRV in hypertensive patients.
METHODS: We conducted a cross-sectional analysis involving hypertensive patients divided based on their apnea-hypopnea index (AHI) into two groups: the AHI ≤ 15 and the AHI > 15. All participants underwent polysomnography (PSG), 24-hour dynamic electrocardiography (DCG), cardiac Doppler ultrasound, and other relevant evaluations.
RESULTS: The AHI > 15 group showed a significantly higher prevalence of frequent atrial premature beats and atrial tachycardia (P = 0.030 and P = 0.035, respectively) than the AHI ≤ 15 group. Time-domain analysis indicated that the standard deviation of normal-to-normal R-R intervals (SDNN) and the standard deviation of every 5-minute normal-to-normal R-R intervals (SDANN) were significantly higher in the AHI > 15 group (P = 0.020 and P = 0.033, respectively). Frequency domain analysis revealed that the low-frequency (LF), high-frequency (HF) components, and the LF/HF ratio were also significantly elevated in the AHI > 15 group (P < 0.001, P = 0.031, and P = 0.028, respectively). Furthermore, left atrial diameter (LAD) was significantly larger in the AHI > 15 group (P < 0.001). Both univariate and multivariable linear regression analyses confirmed a significant association between PSG-derived independent variables and the dependent HRV parameters SDNN, LF, and LF/HF ratio (F = 8.929, P < 0.001; F = 14.832, P < 0.001; F = 5.917, P = 0.016, respectively).
CONCLUSIONS: Hypertensive patients with AHI > 15 are at an increased risk for atrial arrhythmias and left atrial dilation, with HRV significantly correlating with OSA severity.